Lisraya
(Oral Brepocitinib)PreclinicalSmall molecule
Lisraya is one of 20 small molecule programs targeting Sarcoidosis. It is currently in Preclinical.
2
Indications
2
Total Trials
2
Active Trials
19
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
16 competitors in Sarcoidosis
#DrugCompanyPhaseTrials
1Calciferol
Jazz PharmaceuticalsApproved
Daliresp
AstraZenecaApproved
Esbriet
LLegacy Health System
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Decadron
AAspen Global Incorporated
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Glucophage
EMD SeronoApproved
Rapamune
PPrism Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Aug 27, 2026
LISRAYA
NDA NDA220106
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oral Brepocitinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]